Michal Fresser is the CEO of the biotech company Axon Neuroscience, with a passion for advancing biotech solutions, especially in Alzheimer's research. He has participated in projects from initial scientific conception to successfully completed phases 1 and 2 clinical trials. He published the results in recognized scientific journals, which contribute to the advancement of medical knowledge and patient care.